TY - JOUR
T1 - Three Decades of Ultrasound Contrast Agents
T2 - A Review of the Past, Present and Future Improvements
AU - Frinking, Peter
AU - Segers, Tim
AU - Luan, Ying
AU - Tranquart, François
PY - 2020/4
Y1 - 2020/4
N2 - Initial reports from the 1960s describing the observations of ultrasound contrast enhancement by tiny gaseous bubbles during echocardiographic examinations prompted the development of the first ultrasound contrast agent in the 1980s. Current commercial contrast agents for echography, such as Definity, Optison, Sonazoid and SonoVue, have proven to be successful in a variety of on- and off-label clinical indications. Whereas contrast-specific technology has seen dramatic progress after the introduction of the first approved agents in the 1990s, successful clinical translation of new developments has been limited during the same period, while understanding of microbubble physical, chemical and biologic behavior has improved substantially. It is expected that for a successful development of future opportunities, such as ultrasound molecular imaging and therapeutic applications using microbubbles, new creative developments in microbubble engineering and production dedicated to further optimizing microbubble performance are required, and that they cannot rely on bubble technology developed more than 3 decades ago.
AB - Initial reports from the 1960s describing the observations of ultrasound contrast enhancement by tiny gaseous bubbles during echocardiographic examinations prompted the development of the first ultrasound contrast agent in the 1980s. Current commercial contrast agents for echography, such as Definity, Optison, Sonazoid and SonoVue, have proven to be successful in a variety of on- and off-label clinical indications. Whereas contrast-specific technology has seen dramatic progress after the introduction of the first approved agents in the 1990s, successful clinical translation of new developments has been limited during the same period, while understanding of microbubble physical, chemical and biologic behavior has improved substantially. It is expected that for a successful development of future opportunities, such as ultrasound molecular imaging and therapeutic applications using microbubbles, new creative developments in microbubble engineering and production dedicated to further optimizing microbubble performance are required, and that they cannot rely on bubble technology developed more than 3 decades ago.
KW - Contrast agents
KW - Definity
KW - Microbubbles
KW - Monodisperse
KW - Optison
KW - Sonazoid
KW - SonoVue
KW - Ultrasound
KW - 22/2 OA procedure
UR - http://www.scopus.com/inward/record.url?scp=85077753763&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-85077753763&partnerID=MN8TOARS
U2 - 10.1016/j.ultrasmedbio.2019.12.008
DO - 10.1016/j.ultrasmedbio.2019.12.008
M3 - Review article
AN - SCOPUS:85077753763
SN - 0301-5629
VL - 46
SP - 892
EP - 908
JO - Ultrasound in medicine and biology
JF - Ultrasound in medicine and biology
IS - 4
ER -